Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
  • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
  • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
  • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
  • A61L2/186—Peroxide solutions
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
  • A01N37/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group; Thio analogues thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
  • A61L2202/20—Targets to be treated
  • A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps

Definitions

• This invention concerns compositions, processes for the preparation of such compositions, two-pack systems for preparing such compositions and uses of such compositions. More particularly the present invention concerns compositions comprising dilute aqueous solutions of lower aliphatic peracids and their use as disinfectant compositions.
• the lower aliphatic peracids are effective wide-spectrum bactericides which have the particular advantage, in use, of leaving as residues only the corresponding lower aliphatic acids and therefore being particularly suitable for applications which require a non-environmentally-polluting disinfectant. While the lower aliphatic peracids in general are contemplated herein, for example those corresponding to carboxylic aliphatic acids containing 2 to 9 carbon atoms, peracetic acid is particularly envisaged since it is already a commercially important peracid for disinfectant purposes. Where the following description relates to peracetic acid it is to be understood that the other peracids may be read in substitution therefor provided that the technical context allows it.
• Aqueous solutions of peracetic acid containing up to about 45% by weight of peracetic acid are commercially available. Such solutions may be produced by reacting appropriately concentrated hydrogen peroxide and acetic acid in an aqueous medium in the presence of an acid catalyst which is usually sulphuric acid or other strong mineral acid.
• the acid catalyst may be present in from about 0.1 % to about 5% by weight of the reaction mixture.
• Aqueous solutions of peracetic acid represent equilibrium mixtures of the reactants and the reaction products and, under relatively forcing reaction conditions, for example when using one or more of a substantial quantity of
• SUBSTITUTE SHEET catalyst an elevated reaction temperature and a concentrated reaction mixture, equilibrium may be substantially reached in a relatively short time.
• a temperature of from 30°C to 50°C and a concentration of acid above about 20% by weight the reaction mixture may come to equilibrium within hours.
• dilute solutions of peracetic acid for example below 5% by weight but often below 2%, for example from 0.1 % to 2% by weight, are required.
• Such dilute peracetic acid solutions may be produced directly by reacting acetic acid and hydrogen peroxide in a suitably dilute reaction medium but equilibrium can take an extremely long time to reach, particularly at the more extreme dilutions envisaged.
• equilibrium may take a month or more to reach if the reaction is not acid catalysed or a week or more even if the reaction is acid catalysed. This entails a very heavy utilisation of plant and equipment on a large production scale.
• a concentrated equilibrium solution of peracetic acid is diluted with water, the equilibrium point of the system is progressively altered, as dilution progresses, in favour of the regeneration of the original reactants.
• the ageing time taken to attain the new equilibrium point, after dilution is of a similar order to that required to produce such a dilute solution directly from suitable reactants.
• Such a diluted solution may be used directly, although it is not at equilibrium and is therefore of variable composition in storage.
• Such non-equilibrium diluted solutions also have a composition dictated by the equilibrium point applying at the original concentration, which may not be desired in some applications.
• SUBSTITUTE SHEET commercial, e.g. fully equilibrated peracetic acid which has been produced by the use of small amounts of a mineral acid catalyst.
• United States Patent No 4297298 describes the production of an aqueous solution of a lower aliphatic peracid by preparing in a first process step a concentrated solution of the peracid from the corresponding carboxylic acid or anhydride and concentrated hydrogen peroxide in the presence of a small quantity of a strong acid catalyst and diluting the solution with a solution containing at least one of the reagents from the first process step so as to bring the concentration of the aliphatic peracid to the rated concentration of the mixture the concentration of the diluent reagent or reagents being chosen "so that once dilution has been brought about, the system is no longer at equilibrium, but tends to move in the direction of forming further aliphatic peracid at a very slow rate.
• United States Patent No. 4743447 describes the production of solutions having a hydrogen peroxide base for disinfecting contact lenses, the solution having from 0.005% to 0.1 % by weight of peracetic acid, 1 % to 8% by weight of hydrogen peroxide and sufficient acetic acid for the system to reach equilibrium.
• a solution may be prepared by direct reaction using a very dilute reaction mixture with lengthy equilibration or from a stable commercial solution having a "weak concentration" of peracetic acid to which the other constituents of the composition are added. This teaching does not therefore avoid the separate initial step of producing a stable weak solution of peracetic acid from which to produce in turn the final product.
• EP-A-0357238 discloses an anti-microbial composition
• a strong oxidant a copper and brass corrosion inhibitor, a buffering agent, at least one anti-corrosive agent which exhibits corrosion inhibition in at least aluminium, carbon steel and stainless steel, and a wetting agent.
• the corrosion inhibitors specifically disclosed for brass and aluminium comprise triazoles and molybdates, which are known to have unfavourable toxicity, and which therefore renders undesirable their use in a medical environment.
• the peracetic acid composition employed as a disinfectant composition is desirable for the peracetic acid composition employed as a disinfectant composition to be produced by dilution of a more
• a second solution which can comprise components which may confer beneficial properties on the peracetic acid composition, such as corrosion inhibitors.
• the second solution can become contaminated with micro-organisms, for example, moulds and yeasts, during storage prior to mixing with the peracetic acid solution. Control of this is therefore desirable, but many of the compounds commonly recommended for such control are either incompatible with peracetic acid, or can be undesirable for medical use because of their toxicity.
• a process for the preparation of an aqueous disinfectant composition characterised in that the process comprises mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer.
• the present invention provides a disinfectant composition obtainable by a process comprising mixing a first aqueous solution comprising a lower aliphatic peracid with a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer and/or peracid stabilizer. It is to be understood that the peracid composition of the present invention is not in equilibrium and comprises a relatively higher concentration of stabilizer(s) than a skilled person would expect to find in a composition which is in equilibrium and comprises a similar concentration of peracid.
• the present invention provides a two-pack system for the preparation of a disinfectant composition, characterised in that one pack comprises a first aqueous solution comprising a lower aliphatic peracid, and the other pack comprises a second aqueous solution comprising hydrogen peroxide, a corrosion inhibitor and a hydrogen peroxide stabilizer
• the first aqueous solution preferably comprises a lower aliphatic peracid, such as peracetic acid, in an amount of from 2% to 10%, more preferably from 3% to 7%, by weight of the solution.
• the first aqueous solution may additionally comprise stabilizer(s) for the hydrogen peroxide and/or the peracid in the equilibrium solution, each relevant stabilizer being present in a preferred amount of from 20 to 10,000 ppm.
• both the peroxide and peracid are stabilized in the solution, giving a preferred combined stabilizer concentration of from 3000 to 6000 ppm.
• a suitable peracid stabilizer is dipicolinic acid and suitable peroxide stabilizers include phosphonic acids and salts thereof, e.g.
• the products sold by Monsanto under the trade mark "Dequest” such as hydroxyethylidenedimethylene phosphonate, diethylenetriaminepentamethylene phosphonate and ethylenediaminetetramethylene phosphonate and those stabilizers claimed in European patent application 0426949, especially cyclohexane-1 ,2- diaminotetramethylenephosphonic acid and salts thereof (CDTMP).
• CDTMP cyclohexane-1 ,2- diaminotetramethylenephosphonic acid and salts thereof
• the first solution is usually an equilibrium mixture of the relevant reactants and reaction products, as generally described in the paragraph bridging page 1 and page 2 above, and that the above specified amount of peracid indicates the amount of peracid per se in the solution.
• a preferred process for the preparation of dilute solutions of lower aliphatic peracids useful in the present invention is disclosed in PCT Patent Application No. WO 91 /13058.
• the hydrogen peroxide present in the second aqueous solution is preferably present as a dilute solution.
• the concentration of hydrogen peroxide present in the second aqueous solution is unlikely to be greater than about 5% w/w.
• the concentration of hydrogen peroxide is from about 0.025% w/w to about 1 % w/w, most preferably from about 0.05% w/w to about 0.5% w/w and in some embodiments from 0.05% w/w to 0.2% w/w.
• the function of the hydrogen peroxide in the second aqueous solution is to inhibit the growth of microbial contaminants in the solution.
• the second aqueous solution preferably comprises from 0.1 % to 5 %, more preferably from 0.1 % to 1 %, by weight of the solution of a corrosion inhibitor.
• the corrosion inhibitor is an alkali metal phosphate, most preferably a potassium phosphate.
• Dipotassium hydrogen orthophosphate ( 2HPO4) is the most preferred corrosion inhibitor.
• the second aqueous solution preferably comprises from about 0.1 % to
• SUBSTITUTE SHEET about 2%, often 0.1 % to 1 %, more preferably up to 0.7% by weight of the solution of hydrogen peroxide stabilizer and/or peracid stabilizer.
• a hydrogen peroxide stabilizer is used.
• the preferred peroxide stabilizers are phosphonic acids and salts thereof, for example, those described hereinabove as suitable for the first aqueous solution.
• a suitable peracid stabilizer is dipicolinic acid.
• the second aqueous solution comprises from 0.025% to 1 % w/w hydrogen peroxide, from 0.1 % to 0.7% w/w of CDTMP and from 0.1 to 1 % w/w of K2HPO4.
• a two-pack system for the preparation of a disinfectant composition characterised in that one pack comprises a first aqueous solution comprising 3% to 7% w/w peracetic acid, and the other pack comprises a second aqueous solution comprising from 0.025% to 1 % w/w hydrogen peroxide, from 0.1 % to 0.7% w/w CDTMP and from 0.1 % to 1 % w/w of dipotassium orthophosphate.
• Mixing of the first and second solutions give a disinfectant composition immediately after mixing comprising at least about 0.05% and generally not greater than about 1 % by weight peracid.
• the mixture of the two solutions immediately after mixing comprises from about 0.1 % to about 0.25% or from about 0.25% to about 0.5% by weight peracid.
• the mixture also desirably comprises from about 0.1 % to about 5% corrosion inhibitor and from about 0.1 % to about 1 % peroxide stabilizer and/or peracid stabilizer.
• Such mixtures can often be obtained conveniently by selecting a volume ratio of the first solution to the second solution which is often at least 1 : 5 and not usually greater than about 1 : 50, preferably from about 1 : 10 to about 1 : 30, taking into account the concentration of the components in each solution.
• One or both of the aqueous solutions may contain other components useful in disinfectant compositions, e.g. a triazole corrosion inhibitor and/or a wetting agent, though the presence of these components is not essential to obtain the advantages of the invention (indeed, such components may be slightly detrimental).
• One or both of the solutions may contain an indicator, such as, for example, methyl red, which undergoes a colour change to indicate that the two solutions have been mixed together.
• compositions provided by the process of the present invention are not in equilibrium and that in the natural course of
• SUBSTITUTE SHEET events the peracid component of the composition will tend towards equilibrium.
• the composition described in the paragraph immediately above this paragraph will begin to change within a relatively short period of time from mixing the first and second solutions together and that as time passes the peracid concentration in the solution will reduce as it tends towards equilibrium. Normal equilibrium could be expected to be reached after about two days, assuming the peracid and/or peroxide does not decompose in that period.
• compositions of the present invention are particularly suitable for use as medical disinfectants.
• the compositions are used to disinfect medical equipment which has metal, e.g. aluminium, brass, copper and especially steel, components required to be disinfected.
• the composition is particularly useful for disinfection of endoscopes.
• the present invention may have a further advantage over the prior art compositions of Steris.
• the selected components of the invention composition interact to protect metal components, especially steel components, with regard to localised corrosion, eg pitting, as well as, if not better than, if molybdate, triazole and/or wetting agent were present. This is most surprising in light of the disclosure on page 4, lines 7 to 9, of Steris.
• the present invention has the advantage of providing a dilute composition comprising a relatively high concentration of peracid. Furthermore, the process of the present invention enables a relatively longer shelf life for the separate aqueous solution than would be achieved if the composition was supplied per se.
• Example 1 Preparation of Composition according to the Present Invention A solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide, 8% w/w acetic acid was diluted 14 times with a solution containing 0.1 % w/w hydrogen peroxide, 1 % w/w CDTMP (as supplied, 14% active w/w), 0.8% dipotassium hydrogen orthophosphate and 10 ppm 0.01 % methyl red solution to form a solution containing 3,500ppm peracetic acid.
• a solution containing 0.1 % w/w hydrogen peroxide, 1 % w/w CDTMP (as supplied, 14% active w/w), 0.8% dipotassium hydrogen orthophosphate and 10 ppm 0.01 % methyl red solution to form a solution containing 3,500ppm peracetic acid.
• test organisms used were bacteria Staphylococcus aureus, ATCC 6538, Pseudomonas aeruqinosa, ATCC 1 5442 and funous Candida albicans ATCC 10231 .
• the results of the tests showed inhibition of both bacterial and fungal growth in the solution.
• IMI 149007 cell count 2.9 x 10 7 spores/ml
• the samples were stored for 6 months in screw top jars at ambient temperature and regularly analysed for surviving cultures.
• Surviving cultures were enumerated by dilution of 1 ml samples of the solutions in quarter-strength Ringers solution followed by culture as follows. For Staphylococcus aureus and Pseudomonas aeruqinosa. 24hr @ 37°C in Tryptone Soya Broth, for Candida albicans. 72hr @ 37 °C in Tryptone Soya Broth, for Asoeroillus niger.
• the number of surviving colonies was between 1 .3 x 10 ⁇ and 2.4 x 10 7 cfu/ml, with the number being 4.7 x 10 ⁇ cfu/ml after 6 months.
• the solution according to the present invention there were no surviving colonies, except for 24 hours after the addition of Asperqillus niger , when 4 x 10 ⁇ cfu/ml was observed. After a further 24 hours storage, however, there were no surviving colonies.
• compositions according to the present invention gave good inhibition of microbial growth, and could give excellent resistance to microbial contamination over long term storage.
• TITUTE SHEET present invention (Formulation 1 ) containing 0.3% w/w hydrogen peroxide, 0.14% w/w CDTMP (as 100%), 0.8% dipotassium hydrogen orthophosphate, 0.3% benzotriazole and 10 ppm 0.01 % methyl red solution were prepared.
• a further 4 samples containing an additional 0.2% 5 benzotriazole (Formulation 2) were also prepared. Samples were stored for 1 month at each of ambient (ca. 20°C), 28°C, 32°C and 40°C and analysed for hydrogen peroxide content. The results of the analyses showed that for both solutions, there was no loss of hydrogen peroxide at any of the storage temperatures. The samples were also employed to
• compositions according to the present invention containing ca. 3,500ppm peracetic acid by 14 times dilution of a solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide and 8% w/w acetic acid.
• the solutions according to the present invention were analysed for peracetic acid and hydrogen peroxide content, stored for 5 days and then re-analysed
• a solution of 5% w/w peracetic acid, 20% w/w hydrogen peroxide, 8% w/w acetic acid is diluted 25 times with a solution containing 0.3% w/w hydrogen peroxide, 0.14% w/w CDTMP (as 100%, ⁇ 25ppm chloride), 0.8% dipotassium hydrogen orthophosphate and 10 ppm 0.01 % methyl red solution to form a disinfectant solution containing 2,000ppm peracetic acid.
• Duplicate coupons of mild steel and stainless steel 316 are immersed for 72 hours in samples of the disinfectant solution at room temperature (average 20°C) . The disinfectant solution is completely replaced daily with fresh solution. Examination of the coupons on completion of the trial shows only very slight localised corrosion of the coupons.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Plant Pathology (AREA)
• Environmental Sciences (AREA)
• Agronomy & Crop Science (AREA)
• Engineering & Computer Science (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Pest Control & Pesticides (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Apparatus For Disinfection Or Sterilisation (AREA)
• Dental Preparations (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Detergent Compositions (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=10728513

Family Applications (1)

Country Status (33)

Cited By (22)

Families Citing this family (40)

Citations (7)

Family Cites Families (6)

• 1993
  • 1993-01-09 GB GB939300366A patent/GB9300366D0/en active Pending
  • 1993-12-21 IL IL108120A patent/IL108120A/xx not_active IP Right Cessation
  • 1993-12-21 EG EG81393A patent/EG20536A/xx active
  • 1993-12-22 IN IN929MA1993 patent/IN177893B/en unknown
  • 1993-12-24 TW TW082110969A patent/TW252049B/zh active
  • 1993-12-30 SI SI9300695A patent/SI9300695B/sl unknown
  • 1993-12-31 IS IS4117A patent/IS1899B/is unknown
• 1994
  • 1994-01-05 NZ NZ259408A patent/NZ259408A/en unknown
  • 1994-01-05 HU HU9501927A patent/HU216739B/hu unknown
  • 1994-01-05 CA CA002153396A patent/CA2153396C/en not_active Expired - Fee Related
  • 1994-01-05 DE DE69418305T patent/DE69418305T2/de not_active Expired - Lifetime
  • 1994-01-05 CN CN94191139A patent/CN1076164C/zh not_active Expired - Fee Related
  • 1994-01-05 AU AU58203/94A patent/AU686127B2/en not_active Ceased
  • 1994-01-05 CZ CZ19951756A patent/CZ287312B6/cs not_active IP Right Cessation
  • 1994-01-05 WO PCT/GB1994/000010 patent/WO1994015465A1/en active IP Right Grant
  • 1994-01-05 BR BR9406256A patent/BR9406256A/pt not_active IP Right Cessation
  • 1994-01-05 AT AT94903952T patent/ATE179569T1/de active
  • 1994-01-05 ES ES94903952T patent/ES2133534T3/es not_active Expired - Lifetime
  • 1994-01-05 RU RU95118444A patent/RU2145879C1/ru not_active IP Right Cessation
  • 1994-01-05 EP EP94903952A patent/EP0677990B1/en not_active Expired - Lifetime
  • 1994-01-05 US US08/481,323 patent/US5720983A/en not_active Expired - Fee Related
  • 1994-01-05 KR KR1019950702739A patent/KR100317577B1/ko not_active IP Right Cessation
  • 1994-01-05 DK DK94903952T patent/DK0677990T3/da active
  • 1994-01-05 SK SK879-95A patent/SK283238B6/sk unknown
  • 1994-01-05 JP JP6515797A patent/JP2843442B2/ja not_active Expired - Fee Related
  • 1994-01-05 PL PL94309723A patent/PL175085B1/pl not_active IP Right Cessation
  • 1994-01-07 ZA ZA9495A patent/ZA9495B/xx unknown
  • 1994-01-07 HR HR9300366.3A patent/HRP940015B1/xx not_active IP Right Cessation
  • 1994-05-01 UA UA95073178A patent/UA43838C2/uk unknown
• 1995
  • 1995-07-04 OA OA60683A patent/OA10561A/en unknown
  • 1995-07-07 NO NO19952714A patent/NO312431B1/no unknown
  • 1995-07-07 FI FI953351A patent/FI109077B/fi active
• 1999
  • 1999-07-27 GR GR990401941T patent/GR3030857T3/el unknown

Patent Citations (7)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events